CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

F. Birzele, E. Voss, A. Nopora, K. Honold, F. Heil, S. Lohmann, H. Verheul, C. Le Tourneau, J.P. Delord, C Van Herpen, D. Mahalingam, A.L. Coveler, V. Meresse, S. Weigand, V. Runza, M. Cannarile

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2753-2762
JournalClinical Cancer Research
Volume21
Issue number12
DOIs
Publication statusPublished - 2015

Cite this

Birzele, F., Voss, E., Nopora, A., Honold, K., Heil, F., Lohmann, S., ... Cannarile, M. (2015). CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clinical Cancer Research, 21(12), 2753-2762. https://doi.org/10.1158/1078-0432.CCR-14-2141